The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Vincenti et al., N Engl J Med 338(3):161-165 January 15, 1998.

Correspondence
PreviousPrevious
Volume 338:1700-1701 June 4, 1998 Number 23
NextNext

Daclizumab to Prevent Acute Rejection in Renal Transplantation

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Vincenti, F.
-Related Article
by Vincenti, F.
-PubMed Citation
To the Editor: Vincenti et al. (Jan. 15 issue)1 reported that daclizumab, a monoclonal antibody that blocks the interleukin-2 receptor, reduced the frequency of episodes of acute rejection by 37 percent during the first six months after renal transplantation in a study involving mainly U.S. centers. This result is similar to the 34 percent reduction reported in a recent European trial of a similar monoclonal antibody, basiliximab.2 Surprisingly, however, the overall rates of acute rejection were considerably lower in the U.S. study than in the European study (rates in the control groups: 39 percent vs. 52 percent, P=0.02; rates in . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.